Phase I Study of ACTR707, an Autologous T cell Product, in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B Cell Lymphoma
|Effective start/end date||8/1/17 → 8/30/21|
- UNUM THERAPEUTICS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.